# Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer

> **NCT02688023** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1

## Key facts

- **NCT ID:** NCT02688023
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2016-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688023, "Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02688023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*